Literature DB >> 22064460

Targeted therapies: adjuvant bisphosphonates--an option with low estrogen?

Michael Gnant1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22064460     DOI： 10.1038/nrclinonc.2011.170

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

Authors:  H Eidtmann; R de Boer; N Bundred; A Llombart-Cussac; N Davidson; P Neven; G von Minckwitz; J Miller; N Schenk; R Coleman
Journal:  Ann Oncol       Date:  2010-05-05       Impact factor: 32.976

Review 2.  Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.

Authors:  Michael Gnant; Philippe Clézardin
Journal:  Cancer Treat Rev       Date:  2011-10-07       Impact factor: 12.111

3.  The distribution of secondary growths in cancer of the breast. 1889.

Authors:  S Paget
Journal:  Cancer Metastasis Rev       Date:  1989-08       Impact factor: 9.264

4.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

Review 5.  Bisphosphonates and breast cancer prevention.

Authors:  Rowan T Chlebowski; Nananda Col
Journal:  Anticancer Agents Med Chem       Date:  2012-02       Impact factor: 2.505

6.  Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.

Authors:  M Gallo; A De Luca; L Lamura; N Normanno
Journal:  Ann Oncol       Date:  2011-05-06       Impact factor: 32.976

7.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Authors:  Michael Gnant; Brigitte Mlineritsch; Walter Schippinger; Gero Luschin-Ebengreuth; Sabine Pöstlberger; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Vesna Bjelic-Radisic; Hellmut Samonigg; Christoph Tausch; Holger Eidtmann; Günther Steger; Werner Kwasny; Peter Dubsky; Michael Fridrik; Florian Fitzal; Michael Stierer; Ernst Rücklinger; Richard Greil; C Marth
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

8.  The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.

Authors:  R E Coleman; M C Winter; D Cameron; R Bell; D Dodwell; M M Keane; M Gil; D Ritchie; J L Passos-Coelho; D Wheatley; R Burkinshaw; S J Marshall; H Thorpe
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

9.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245
  9 in total
  1 in total

Review 1.  The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.

Authors:  P Hadji; R Coleman; M Gnant; J Green
Journal:  Ann Oncol       Date:  2012-06-22       Impact factor: 32.976
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.